Treatment of Cancer-anorexia Using Megestrol Acetate Concentrated Suspension in Lung or Pancreatic Cancer Patients

PHASE3TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

September 30, 2006

Study Completion Date

September 30, 2006

Conditions
AnorexiaCachexiaWeight Loss
Interventions
DRUG

Megestrol acetate concentrated suspension 110 mg/mL

Megestrol acetate concentrated suspension 110 mg/mL given as an oral dose of 550 mg (5 mL) once per day for 56 days, with an optional 28 days extension phase

DRUG

Placebo

Placebo oral suspension, 5 mL once daily

Trial Locations (3)

21502

Western Maryland Health System, Cumberland

29464

Lowcountry Hematology & Oncology, PA, Mt. Pleasant

33179

Innovative Medical Research of South Florida, Inc, Miami

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

PRA Health Sciences

INDUSTRY

lead

Par Pharmaceutical, Inc.

INDUSTRY